Aptinyx Investor Relations Material
Latest events
Q3 2022
Aptinyx
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Aptinyx Inc
Access all reports
Aptinyx Inc. is a biopharmaceutical company focused on developing therapies for neurological disorders. The company leverages its expertise in small-molecule compounds that modulate NMDA receptors to address conditions such as chronic pain, post-traumatic stress disorder, and cognitive impairment. Aptinyx’s research and development efforts aim to create innovative treatments for patients with unmet medical needs. The company is headquartered in Evanston, Illinois, and its shares are listed on the NASDAQ.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
APTX
Country
🇺🇸 United States